Jakarta - The Extraordinary General Meeting of Shareholders (EGMS) of PT Kimia Farma Tbk (KAEF) approved the plan to issue new shares to increase capital with Pre-emptive Rights for a maximum of 2,779,397,000 series B shares with a nominal value of Rp 100 per share through the mechanism of Limited Public Offering.

"The funds obtained will be used to meet maturing loan payments, working capital, and business development, including in the context of digital transformation and information technology systems," said KAEF President Director Verdi Budidarmo in a statement on Thursday (19/8).

In the EGMS, the shareholders also agreed to change the nomenclature and composition of the KAEF management. The EGMS approved and appointed Jasmine Kamiasti Karsono as Director of Portfolio & Business Development and changed the nomenclature of the management, namely Imam Fathorrahman as Director of Marketing & Commercial, who previously served as Director of Busi